Form 4: Vertex Pharmaceuticals Director Bruce Sachs Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director Bruce Sachs exercised stock options and sold shares of Vertex Pharmaceuticals (VRTX) on May 22, 2024, under a pre-arranged trading plan.
Summary
- On May 22, 2024, Bruce Sachs, a director of Vertex Pharmaceuticals, exercised stock options to acquire 7,073 shares of common stock at a price of $93.51 per share.
- Simultaneously, Sachs sold 7,073 shares of Vertex Pharmaceuticals common stock at $448 per share.
- Following these transactions, Sachs directly owns 40,000 shares of Vertex Pharmaceuticals common stock.
- The transactions were executed under a company-approved trading plan (Rule 10b5-1) established on February 12, 2024.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports routine transactions under a pre-arranged trading plan.
Industry Context
Executive stock transactions are common and closely monitored, especially in the pharmaceutical industry, to gauge insider sentiment and potential future performance. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 02/12/2024 | Date of entry into Rule 10b5-1 trading plan |
| 05/22/2024 | Date of stock option exercise and share sale |
| 05/31/2026 | Expiration date of stock options |
| 05/24/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.